Jagsonpal targets INR500 crore revenue by FY28 after strong Q2 growth

Management guided margin improvementMulti-year targets disclosedInvestor Communications View source PDF Explain this filing

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.8%Reaction day

₹216.99

prior close

₹217.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+2.2%-0.4% vs market

Pharmaceuticals peers, median of 173sector+0.8%+1.0% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 1.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

+0.4

15m

+0.4

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.8+2.2-0.4+0.8+1.0

Next day

+1.3+3.3-2.0+1.6-0.3

-1.9pendingpending+1.5-3.4

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 standalone revenue rose 9.3% to INR81 crore and consolidated revenue rose 29% to INR96 crore, including Aequitas. H1 consolidated revenue was INR179 crore, profit after tax INR12 crore and cash above INR135 crore. Group Pharma's wellness business is being integrated. Management targets Q3 revenue above INR100 crore, FY28 revenue of INR500 crore and a consolidated EBITDA margin near or above 22%.

Likely market impact

Acquisitions lift growth and add hospital and wellness channels, though integration and lower-margin sales may cap near-term consolidated margins.